[1] Thompson IO, van der Bijl P, van Wyk CW, et al. A comparative light-microscopic, electron-microscopic and chemical study of human vaginal and buccal epithelium[J]. Arch Oral Biol, 2001, 46(12):1091-1098. [2] Davis CC, Kremer MJ, Schlievert PM, et al.Penetration of toxic shock syndrome toxin-1 across porcine vaginal mucosa ex vivo: permeability characteristics, toxin distribution, and tissue damage[J]. Am J Obstet Gynecol, 2003, 189(6):1785-1791. [3] D’Cruz OJ, Erbeck D, Uckun FM. A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate[J]. Toxicol Pathol, 2005, 33(4):465-476. [4] Wikinson D, Tholandi M, Ramjea G, et al.Nonoxynol-9 Apermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: sgstematic review and meta-analgsis of randomized controlled trials including more than 5000 women[J]. Lancet Infect Dis, 2002, 2(1):613-617. [5] Obiero J, Mwethera PG, Hussey GD, et al.Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta- analysis[J]. BMC Infect Dis, 2012, 12(5):289-310. [6] Patton DL, Cosgrove SY, Paul KJ.A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model[J]. Sex Transm Dis,2008, 35(10):889-897. [7] Peuster M, Fink C, Reckers J, et al.Assessment of subacute inflammatory and proliferative response to coronary stenting in a porcine model by local gene expression studies and histomorphometry[J]. Biomaterials, 2004, 25(6):957-963. [8] Catalone BJ, Kislr-Catalone TM, Budgeon LR, et al.Mouse model of cericoraginal toxicity and inflammation for preclinical eraluation of topical vaginal microbicides[J]. Antimicrob Agents Chemother, 2004, 48(5):1837-1847. [9] Lard-Whiteford SL, Matecxcka D, O'Rear JJ, et al. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update[J]. J Acquir Immune Defic Syndr, 2004, 36(1):541-552. [10] D’Cruz OJ, Uckun FM. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat[J]. Toxicol Pathol, 2007, 35(7):910-927. [11] Doncel GF, Chandra N, Fichorova RN.Preclinical assessment of the proinflammatory potential of microbicide candidates[J]. J Acquir Immune Defic Syndr, 2004, 37(Suppl 3):S174-S180. [12] Zalenskaya IA, Cerocchi OG, Joseph T, Donaghay MA, et al.Increased cox-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection[J]. Am J Reprod Immunol, 2011, 65(2):569-577. [13] Cummins JE, Doncel GF.Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety[J]. Sex Transm Dis, 2009, 36(3 Suppl):S84-S91. |